Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
ACMR ACM Research Inc
SDY SPDR® S&P Dividend ETF
DIS Walt Disney Co
AAPL Apple Inc
MLM Martin Marietta Materials Inc
GOOG Alphabet Inc
FCNTX Fidelity® Contrafund® Fund
MSFT Microsoft Corp
GLPG Galapagos NV
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Price
Delayed
$9.50
Day's Change
-0.0799 (-0.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.59
Day's Low
7.61
Volume
(Average)

Today's volume of 103,192,318 shares is on pace to be in-line with OCGN's 10-day average volume of 183,013,066 shares.

103,192,318

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.